← Leaderboards
Regina M Myers
Children'S Hosp Of Philadelphia
$539,966
Attributed
$539,966
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $180.9K · FY2023–25$200K$150K$100K$50K$0
'23
'24
'25
Funding mix
By agency
NIH$539,966 · 1
By mechanism
K08$539,966 · 1
Top collaborators
No co-investigators on record.
Most similar at Children'S Hosp Of Philadelphia
Same institution · by research overlap
- Julie R Park$6,704,912
- David T. Teachey$3,927,557
- Kristina Ann Cole$1,757,336
- John M Maris$30,818,378
- Elizabeth Rachel Alpern$5,521,579
Others in their field
Other Rising Stars on “Antigen Targeting”
- Jason Dickens · Duke University$12,259,409
- Suma Babu · Massachusetts General Hospital$9,673,541
- Sabrina Paganoni · Massachusetts General Hospital$9,673,541
- Gregory Sorenson · University Of Maryland Baltimore County$9,161,697
- Li Liang · University Of California-Irvine$7,511,446
- Kai Xu · Ohio State University$4,891,156
Research focus
Antigen TargetingAwardB-Cell Acute Lymphoblastic LeukemiaBiological MarkersCancer Clinical TrialCancer ImmunotherapyCareerCar T Cell TherapyCd19 AntigensCd19 GeneCell TherapyChemotherapyChildChildhoodChimeric Antigen Receptor T CellsClinical EpidemiologyClinical InvestigatorClinical ResearchClinical TrialsClinical Trials DesignCohortComparative EffectivenessComparative Effectiveness StudyAdult
Grant awards (3)
Optimizing outcomes for children and young adults with relapse of B-cell acute lymphoblastic leukemia after CD19-targeted chimeric antigen receptor T-cell therapy$180,885
K08 · FY2025 · CA · contact PI
Optimizing outcomes for children and young adults with relapse of B-cell acute lymphoblastic leukemia after CD19-targeted chimeric antigen receptor T-cell therapy$179,076
K08 · FY2024 · CA · contact PI
Optimizing outcomes for children and young adults with relapse of B-cell acute lymphoblastic leukemia after CD19-targeted chimeric antigen receptor T-cell therapy$180,005
K08 · FY2023 · CA · contact PI